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Abstract A substantial proportion of patients with
advanced thyroid carcinoma fail to respond to or at some
point become refractory to conventional therapies. This
resistance and the phenomena of thyroid cancer progres-
sion and metastasis themselves are thought to be related to
tumor-cell sub-populations with stem-like properties. We
isolated thyrospheres from four advanced thyroid carcino-
mas that were resistant to radioiodine therapy and analyzed
their molecular profiles. ALDH activity and proteomic
profile of main stem cell markers were used to assess stem
cell properties. The TaqMan Low Density Array approach
was used to evaluate the expression of several genes
involved in the EMT process. The phosphorylation status
of tyrosine kinase receptors (RTKs) was analyzed to
identify potential markers for targeted therapies. We then
investigated the effects of the EMT-inhibitor crizotinib on
both cell proliferation and phosphorylation status of RTK
targets. The cancer stem-like properties of a subset of cells
from primary cultures of each tumor were demonstrated. A
wide variability among thyrospheres arising from the four
thyroid cancers in terms of ALDH activity, stem cell
marker expression, and phosphoproteome profiling was
present. Dysregulated expression of genes involved in the
EMT was observed in all four thyrosphere lines. Treatment
with crizotinib was ineffective in cancer stem-like cells,
suggesting the presence of a mechanism of resistance in
thyrospheres. Collectively, our data indicate that thyroid
cancer stem-like populations vary markedly from tumor to
tumor and require detailed molecular and biological char-
acterization if they are to be used as the basis of ‘‘per-
sonalized’’ treatment of aggressive disease.
Keywords Metastatic thyroid cancer  Epithelial-
mesenchymal transition  Cancer stem cells  Drug
resistance
Introduction
Radioactive iodine ablation (131I administration) is currently
the only effective treatment available for recurrent or
metastatic papillary or follicular thyroid cancers. However,
in two out of three patients with this type of disease, the
tumors are characterized by defective uptake/concentration
and/or decreased sensitivity to 131I [1, 2] caused in most
cases by the loss of functional sodium/iodide symporter
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(NIS) expression [3–7]. Current evidence suggests that the
spread of neoplastic disease and its resistance to conven-
tional therapies are largely mediated by the so-called cancer
stem cells [8], a relatively small subpopulation of tumor cells
with the capacity for self-renewal [9]. Cancer stem-like cells
(CSCs) have been identified in thyroid cancer tissues and
continuous cell lines, and their stem-like properties appear to
be closely related to the epithelial-mesenchymal transition
(EMT), a process that is also involved in the physiological
remodeling of tissues and cells during embryogenesis [10–
13]. The EMT is characterized by repressed expression of
E-cadherin and other adhesionmolecules and the acquisition
of mesenchymal features, which allow the cell to migrate to
distant sites [14]. Indeed, in a study of human breast
epithelial cells, the acquisition of mesenchymal traits was
associated with the expression of known stem cell markers,
and transformed cells that had undergone EMT displayed
increased efficiency in the formation of spheres, soft agar
colonies, and tumors. These findings imply that, in addition
to enabling cancer cells to spread, the EMT program also
sustains their capacity for self-renewal [15]. Characteriza-
tion of CSCs from particularly aggressive thyroid cancers
might thus reveal potentially useful information for novel,
targeted treatments for these tumors.
In the present study, we explored the molecular profiles
of thyrospheres derived from four metastatic thyroid can-
cers characterized by resistance to radioiodine therapy.
Particular attention was focused on their expression of
EMT-related genes, the activation status of EMT-related
tyrosine kinase receptors (RTKs), and their responses to the
broad-spectrum RTK inhibitor crizotinib.
Materials and methods
The study protocol was approved by the local ethics
committee, and written informed consent was obtained
from each patient whose tissues were used. Unless other-
wise stated, all commercial products mentioned below
were used according to the manufacturer’s instructions
and/or protocols.
Thyroid tissue collection
Tumor tissue samples were collected from four patients
who consecutively underwent surgery in our hospital for
primary, locally recurrent, and/or metastatic thyroid can-
cer, which had displayed resistance to radioiodine-based
therapy. All tissue specimens were submitted for standard
histopathological examination by two different patholo-
gists, who confirmed the neoplastic phenotype. Clinical
data on each case were collected from hospital charts, and
tumors were staged according to the criteria of American
Joint Committee on Cancer [16]. Molecular characteriza-
tion of all tissue specimens was performed by Sanger
Sequencing analysis of hot spots in thyroid cancer driver
genes [i.e., BRAF (exon 15); HRAS (exon 2,3); KRAS
(exon 2,3); NRAS (exon 2,3); TP53 (exons 5–9); PTEN
(exons 5–8)]. Details on mutation analysis have been pro-
vided elsewhere [17, 18]. For primers contact the authors.
Primary cell cultures and thyrosphere generation
After meticulous removal of fibrous tissues, the surgical
specimens were minced with sterile scissors and incubated
for 1 h at 37 C in digestion medium consisting of DMEM/
F12 1:1 and collagenase IV (1 mg/ml) (Gibco-BRL Divi-
sion, Life Technologies, Foster City, CA). The resulting
cell suspension was plated onto DMEM/F12 medium
(Gibco-BRL, Life Technologies) containing 10 % fetal
bovine serum (Invitrogen, Life Technologies), glutamine
(2 millimol l-1), and Gibco Antibiotic–Antimycotic solu-
tion (Gibco-BRL) and incubated at 37 C in an atmosphere
of 5 % CO2. After isolation, partial trypsinizations have
been carried out in order to separate primary PTC cells
from all other contaminating cells, according to previously
published protocols [19, 20]. In addition, primary tumor
cells were negatively selected using magnetic anti-fibrob-
last beads (Miltenyi Biotec GmbH, Germany) after the first
passage, according to manufacturer’s instructions. The
isolated primary cultures have been maintained from
1 week to 4 weeks prior to switch them to the CSC
medium.
To obtain thyrospheres, primary cell lines were seeded
at a density of 3 9 106 cells into low adhesion flasks
(25 cm2) (Corning, NY, USA) containing CSC medium
[DMEM/F12, glutamine (2 millimol l-1)], Gibco Antibi-
otic–Antimycotic solution, and a mixture of hormones [21,
22]. The medium was supplemented with epidermal growth
factor (EGF) (20 ng/ml) and basic fibroblast growth factor
(bFGF) (20 ng/ml), both obtained from Sigma-Aldrich
Chemicals. Before experiments, the absence of myco-
plasma in each cell line was verified with the EZ-PCR
Mycoplasma Test Kit (Biological Industries, Israel Beit-
Haemek LTD, Israel).
Self-renewal capability for three lines was determined
using extreme limiting dilution analysis (ELDA, an online
tool for limiting dilution analysis; http://bioinf.wehi.edu.
au/software/elda/) (data not shown).
ALDEFLUOR assay and flow cytometry
Aldehyde dehydrogenase (ALDH) activity was assessed in
samples (2x104 cells) of four cell lines using the ALDE-
FLUOR kit (StemCell Technologies, Vancouver, Canada).
Intracellular fluorescence was measured by flow cytometry
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(FACS Canto and FACSAria, Becton–Dickinson, San Jose,
CA, for analysis and sorting, respectively). Sorting gates
were established based on the results of negative controls
consisting of cells pretreated with the specific ALDH
inhibitor diethylaminobenzaldehyde (DEAB).
Total protein extraction for assessment
of pluripotency biomarker expression and RTK
phosphorylation
Thyrospheres and primary cell culture pellets were lysed in
40 ll of lysis buffer containing TrisHCl (pH 7.4, 50 mil-
limol l-1), NaCl (150 millimol l-1), Triton (1 % v/v),
ethylenediaminetetraacetic acid (EDTA, 20 millimol l-1),
phenylmethylsulfonyl fluoride (PMSF, 2 millimol l-1),
protease and phosphatase inhibitors (2X), leupeptin (2 lg/
ml), glycerol (10 % v/v), and water. Total protein was
extracted on ice and quantified with the BCA Protein Assay
(Pierce, Rockford, IL, USA). Results were read in a Nan-
odrop2000 spectrophotometer (Thermo Scientific).
The lysate was then assayed with the Human Pluripotent
Stem Cell Array and Human Phospho-RTK array kits (both
from R&D Systems, Minneapolis, MN). Stem cell markers
(i.e., Oct3/4; Nanog; SOX2; E-chaderin; Gata-4; FoxA2;
IPF1; SOX17; Otx2; TP63; Goosecoid; Snail1; VEGFR2;
HCG; AFP) and phosphorylated RTKs were detected using
chemiluminescence western blotting with Clarity Western
ECL substrate (BIO-RAD) and a charge-coupled device
camera (Chemidoc, BIO-RAD, Hercules, CA, USA).
RNA extraction, RT-PCR, and screening
with the TaqMan Low Density Array (TLDA)
RNA was extracted from primary cell cultures and thyro-
spheres with the RNeasy Mini Kit (Qiagen, Venlo,
Netherlands). Its concentration and purity were assessed by
measuring the optical density (OD) at 260 and 280 nm with
a Nanodrop 2000 spectrophotometer.
Total RNA was reverse transcribed using the High
Capacity cDNA Reverse Transcription kit (Life Tech-
nologies). One hundred nanograms of each cDNA were
used as a template for analysis with the real-time PCR-
based custom TaqMan Low Density Array (TLDA, Life
Technologies), which contains specific predesigned assays
for expression levels of 48 genes (TaqMan Gene Expres-
sion Assays, Life Technologies), including thyroid-specific
differentiation markers and key genes involved in the
EMT. Four housekeeping genes (ACTB, B2 M, GAPDH,
and HRPT1) were included in each array to normalize raw
data. The reaction set-up and amplification in the ABI
PRISM 7900HT Sequence Detection System (Life Tech-
nologies) have been described elsewhere [23].
Cell proliferation and RTK phosphorylation
after exposure to crizotinib
For proliferation assays, cells were seeded into 96-well
plates in quadruplicate and treated for 48 h with crizotinib
(PF-2341066 purchased from Selleck, Houston, TX) at
concentrations of 1 and 10 micromol l-1 (in DMSO) or
with DMSO alone, as described in Zhou et al. [24]. Pro-
liferation was evaluated with the alamarBlue (AB) assay
(Life Technologies). Samples of the primary cultures and
their CSC subsets were seeded into 96-well plates (5 9 103
and 10 9 103 cells/well, respectively), and AB was added
directly to the culture medium (final concentration: 10 %
v/v). After 24, 48, and 72 h of incubation, the OD of the
plate was measured at 550 and 620 nm with a standard
spectrophotometer. As a negative control, AB was added to
the medium without cells. The half maximal inhibitory
Fig. 1 Phase-contrast images of primary thyroid cancer cell lines 1–4
and the thyrospheres derived from each cell line. Primary cell lines
were established from 4 aggressive thyroid cancers. The thyrospheres
were derived from primary cultures after 1 week of growth in stem
cell medium supplemented with EGF and bFGF. Scale bar 200 lM
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concentration (IC50) values were evaluated by nonlinear
regression analysis with Prism 5.04 (GraphPad Software,
La Jolla, CA). The number of viable cells correlates with
the magnitude of dye reduction. Results were expressed as
percentage of AB reduction [25] after correction for
background values observed in negative controls.
For Human Phospho-RTK array analysis, cells were
seeded into 6-well plates and treated for 48 h with crizotinib
at concentrations of 0.05 micromol l-1 (primary line 1), 0.2
micromol l-1 (primary line 2), 1 micromol l-1 (primary line
4), and 1.5 micromol l-1 (CSC lines 1, 2, and 4).
Data analysis
Human Pluripotent Stem Cell Array results were analyzed
with MyImage Analysis software (Thermo Scientific Inc,
Rockford, IL USA). Human Phospho-RTK array results
were analyzed using ImageLab software (Chemidoc BIO-
RAD). In both cases, the signal of each spot was normal-
ized to the mean signal of the negative controls (back-
ground) present on the membrane.
Expression Suite software (Life Technologies) was used
for gene expression analysis with the comparative Ct
(DDCt) method and for assessing the expression of the
target genes normalized to a calibrator (primary cancer
cells). The ACTB gene was used to normalize data because
of its low variation among the samples. The detection
threshold was set at 35. Data are expressed as means (SD).
Statistical significance was assessed with the Student’s
t test, and results were considered significant when P val-
ues were\0.05.
Results
Thyrosphere formation
Primary cell lines were established from three poorly dif-
ferentiated thyroid cancers (primary tumor—line 4; locally
recurrent lesion—line 2; lymph node metastasis—line 1)
and one follicular-variant papillary thyroid cancer (lymph
node metastasis—line 3). The clinical, pathological, and
genetic characteristics of each case are reported in Sup-
plementary Table 1 and Supplemental Fig. 1. After three
passages, 3 9 106 cells of each line were cultured under
stem-like conditions to allow selective proliferation of
immature tumor cells. Within 24 h, thyrosphere formation
was observed as the organization of small aggregates of
cells floating in suspension (Fig. 1). The thyrospheres were
maintained for at least 1 month. When plated under the
same conditions, cells dissociated from the spheres gen-
erated secondary thyrospheres (data not shown), thus
demonstrating their capacity for self-renewal.
Assessment of stem cell-like properties
ALDH activity
Because enhanced ALDH activity appears to be a hallmark
of CSCs [26–28], the four primary thyroid cancer cell lines
were subjected to ALDEFLUOR assay by FACS analysis
(Fig. 2). The percentage of ALDHhigh cells varied widely
(4.7–29.9 %), with higher figures recorded in cell lines 1
and 2 than in those derived from cell line 3 or cell line 4.
Fig. 2 Aldehyde dehydrogenase activity in primary cell lines 1–4.
ALDH activity was measured with the Aldefluor assay. Left-hand
panels The ALDH inhibitor DEAB was added to each sample before
staining, as a control for background fluorescence. Results were used
to confirm the gating area. Right-hand panels Samples assayed
without DEAB pretreatment. P2, P3, and P5: Cell populations with
high, intermediate, and low ALDH activity, respectively. The
percentage of P2 (ALDHhigh) is reported in the lower right corner
of each graph. x-axis: intensity of emitted fluorescence expressed on a
logarithmic scale; y-axis: cell size (side scatter or SSC)
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These data suggest that ALDH activity is restricted to a
subpopulation of cells of the thyroid tumors characterized
by substantial individual variability.
Expression of stem cell markers
We decided to further analyze the expression of several
stem cell markers in the unsorted thyrosphere cell popu-
lations. Total protein extracts from primary cultures and
from thyrosphere cells grown for 1 week under stem cell-
like conditions were thus assayed for the expression of 15
established markers of pluripotency with the Human
Pluripotent Stem Cell Array Kit.
The expression level of each marker varied substantially
from one cell line to another. Thyrospheres from cell line 1
displayed significant overexpression of markers Oct3/4 and
SOX2 relative to the primary cell line derived from the
same tumor (Fig. 3a). Significant differential expression in
thyrosphere cells was more common in cell line 2,
involving seven markers with upregulated expression
(SOX2, E-cadherin, FoxA2, IPF1, SOX17, TP63, and
Snail), and 1 (Oct3/4) that was downregulated relative to
primary cultures (Fig. 3b). In cell line 3, three stem cell
markers were expressed exclusively in the thyrosphere
cells (SOX2, GOOSECOID, and E-CADHERIN), and six
others (Nanog, GATA-4, SOX17, OTX2, VEGFR2, and
HCG) were significantly overexpressed in these cells, as
compared with primary tumor cells (Fig. 3c). As for cell
line 4, significant differences between thyrosphere and
primary cells were found for only two of the 15 markers
(HCG and AFP), both of which were overexpressed in
thyrospheres (Fig. 3d).
These data are fully consistent with the inter-tumor vari-
ability of thyrosphere populations highlighted by the ALDE-
FLUOR assay data. The significant increase in the expression
of pluripotency markers, and in particular of SOX2, under
stem cell culture conditions supports the identification of
thyrosphere cells of all four cell lines as CSCs.
Fig. 3 Expression of pluripotency-related proteins by thyrosphere
cells. Expression levels of pluripotency markers were measured in
total cell extracts with the Proteome Profiler Human Pluripotent Stem
Cell Array kit. Thyrosphere cells were tested after 1 week’s growth
under stem cell conditions and results compared with those obtained
in primary cell cultures from the same tumor. Differences were
assessed with the Student’s t test (*p\ 0.05; **p\ 0.01;
***p\ 0.001). Data are expressed as background- and area-normal-
ized pixel intensity. Error bars represent standard deviation
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Differential expression of EMT-related genes
in thyrospheres
The TaqMan Low Density Array (Life Technologies) was
used to comparatively analyze the expression of genes
involved in thyroid differentiation and those considered
markers of the EMT in thyrospheres and primary cell
cultures from each of the four cancers. As expected, given
the poorly differentiated status of the tissues, all of the cells
analyzed (primary cultures and thyrospheres) were char-
acterized by undetectable levels of NIS, TSHR, and TPO
transcript and very low levels of TG, TTF1, and PAX8
mRNA (Supplemental Fig. 3). Comparative analysis (thy-
rospheres vs primary tumor cells) revealed sometimes
higher expression of the last three genes. This behavior
could be not surprising considering their early expression
also in embryogenesis [29]. The EMT-related gene
expression profiles of the four cell lines are reported in full
in both Supplemental Table 2 and Supplemental Fig. 2.
Fourteen genes displayed significant differential expression
(upregulation, in most cases) in all four CSC populations
(vs. the primary cell cultures) of all four lines (Fig. 4).
RTK phosphorylation patterns in primary
and thyrosphere populations
Next, to identify potential therapeutic targets, we assessed
phosphorylation levels of six RTKs known to be EMT-
related [30–33] in thyrosphere and primary tumor cell
populations. This analysis was restricted to cell lines 1, 2,
and 4; cell line 3 was excluded from this and subsequent
analyses because the thyrosphere population had been
exhausted in the previous experiments.
Figure 5 shows the RTKs found to be activated in the
primary and thyrosphere populations of each cell line. The
results varied widely from one cell line to another. In line
1, ALK and EGFR showed high phosphorylation levels in
both thyrospheres and primary cultures (Fig. 5a). In line 2,
five of the six RTKs assessed were highly phosphorylated
in primary culture cells and less phosphorylated in the
thyrosphere populations (Fig. 5b). In line 4, all RTKs
assessed were substantially phosphorylated in the primary
cultures and thyrosphere populations, an increase in the
phosphorylation levels of DTK were however noted in
thyrosphere line 4 (Fig. 5c). These data indicate the
Fig. 4 EMT-related genes exhibiting significant differential expres-
sion in thyrospheres and primary cell populations from all 4 tumors.
Columns (error bars) represent means (±SD) of two samples tested
with TLDA. Differences between thyrosphere expression levels and
those of corresponding primary cells (calibrator) were assessed with
the Student t test (p\ 0.05 in all cases)
150 Endocrine (2016) 53:145–156
123
Fig. 5 Receptor tyrosine kinase (RTK) phosphorylation levels in
thyrosphere populations. RTK phosphorylation levels were measured
in total protein extracts with the Human Phospho-RTK Array. Results
are shown for primary and CSC lines representing tumors 1, 2, and 4.
RTKs represented are those known to be involved in the EMT
process. Data are expressed as background-normalized pixel intensity.
Error bars represent standard deviation. Statistical significance was
assessed with the Student’s t test (*p\ 0.05; **p\ 0.01;
***p\ 0.001)
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activation of specific RTK in each cell line; moreover, in
primary and thyrosphere subsets from all three lines, at
least one EMT-related RTK was highly activated.
Effect of crizotinib on the proliferation of primary
culture cells and thyrospheres
Given the dysregulation of EMT-related genes and the
RTK phosphorylation levels observed in the three thyroid
cancer cell lines, we decided to evaluate the responses of
these cells to the multiple tyrosine kinase inhibitor crizo-
tinib [34, 35].
Thyrosphere viability in lines 1, 2, and 4 was investi-
gated after 48 h of exposure to crizotinib concentrations
ranging from 1 to 10 micromol l-1 (as previously descri-
bed in [24]) and the half maximal inhibitory concentration
(IC50) calculated for each line. As shown in Fig. 6, pro-
liferation of CSCs from lines 1, 2 and 4 was not signifi-
cantly inhibited, even by the maximal dose tested (Fig. 6a).
In contrast, cells from the primary cultures of lines 1, 2,
and 4 (Fig. 6b) were all sensitive to treatment with crizo-
tinib with IC50 ranging from 9 to 10 micromol l
-1.
The responses observed in these experiments might be
attributed to the different RTK activation patterns observed
in the three cell lines. To explore this possibility, we ana-
lyzed the inhibitory activity of crizotinib on the phospho-
rylation of nine RTKs that were EMT-related and/or
known crizotinib targets in cell lines 1, 2, and 4 (primary
cultures and thyrospheres). The crizotinib concentrations
used in these experiments were approximately one-fourth
the IC50 values shown in Fig. 6. As in previous experi-
ments, the responses of the three cell lines were appre-
ciably different (Fig. 7). In cells from all three primary
cultures, crizotinib decreased the phosphorylation of ALK,
a known target of the drug (Fig. 7a–c). As for the thyro-
sphere, line 1 responded to crizotinib treatment with
upregulated phosphorylation of RTKs known to be direct
targets of the drug (i.e., TRKA, TRKB, and AXL)
(Fig. 7d); thyrosphere line 2 displayed an increase of
phosphorylation levels of all the targets of crizotinib
assessed, a downregulated phosphorylation of PDGFRB
(which is not a direct target of the drug), as well as a huge
increase of EGFR phosphorylation (Fig. 7e). As for the
thyrosphere, line 4 displayed significant post-treatment
downregulation of PDGFRB phosphorylation, together
with a very substantial decrease in DTK phosphorylation
(Fig. 7f).
Discussion
Treatment of radiorefractory thyroid cancer is still an
unresolved issue and elucidation of the cellular pathways
involved in the tumorigenic process may help to choose a
more appropriate targeted treatment [36].
In the present study, we established primary cell cultures
from four aggressive, 131I-refractory thyroid cancers and
obtained cells with stem cell properties to analyze func-
tional features of this cell subset. The thyrospheres varied
widely in terms of their stem cell marker profiles. All,
Fig. 6 Effect of crizotinib exposure on proliferation of primary cell
lines 1, 2, and 4 and their corresponding thyrosphere cells. Percentage
of growth inhibition observed in thyrosphere lines (a) and primary
cell lines (b) after 48 h exposure to crizotinib at concentrations of 1
micromol l-1 and 10 micromol l-1. Curves correspond to a
representative results of experiments performed in triplicate. The
table below each graph summarizes the IC50 of crizotinib calculated
on the basis of three independent experiments
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however, were characterized by upregulated expression of
several EMT-related genes with respect to that observed in
the primary cells from the same tumors. As for EMT-re-
lated RTKs (PDGFRB, ALK, MET, AXL, DTK, EGFR), at
least one was activated in the three thyrosphere line tested,
although on the whole they displayed less activated RTKs
than primary cells. This behavior could be probably
addressed to a quiescent or slow-cycling state of thyro-
sphere cells as compared to primary tumor cells. The
molecular profiles of the CSC-enriched population also
varied widely from one tumor subtype to another, and
differences were even observed between tumors of the
same subtype. Although the number of tumors analyzed in
our study was admittedly limited, our data suggest that the
factors sustaining the pluripotency of thyrospheres differ
with the tumor histotype. In fact, the expression of SOX2
and SOX17 was significantly upregulated in thyrospheres
1, 2, and 3 (relative to primary cells). However, no sig-
nificant difference was observed between SOX2 expression
levels in primary and CSC lines from tumor 4, and SOX17
Fig. 7 Effect of crizotinib exposure on RTK phosphorylation in
primary cell lines 1, 2, and 4 and their corresponding thyrosphere
cells. RTK phosphorylation levels were measured after 48 h exposure
to crizotinib in primary cell cultures (concentrations: 0.05 micromol
l-1 in line 1, 0.2 micromol l-1 in line 2, and 1 micromol l-1 in line 4)
(a–c) and thyrosphere cells (d–f) at a concentration of 1.5 micromol
l-1. Data are expressed as background-normalized pixel intensity.
Error bars represent standard deviation. Statistical significance was
assessed with the Student’s t test (*p\ 0.05; **p\ 0.01;
***p\ 0.001)
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expression was actually downregulated in the thyrospheres
subset. SOX2 upregulation has been reported in several
types of adult stem/progenitor cells and a variety of
malignant tumors, where it can promote tumor growth even
in the absence of Oct4 [37–40]. In a more recent study [41],
downregulation of SOX2 in a human undifferentiated
thyroid cancer cell line rendered the cells sensitive to cis-
platin and doxorubicin treatment. As for SOX17, it seems
to be involved in a switch that converts the Oct4 complex
from a pluripotency regulator to an endodermal gene
activator [42, 43].
Although TLDA analysis revealed marked variability
between the thyrospheres in terms of gene expression
profiles, all four were characterized by overexpression of
many important EMT-related genes relative to the primary
cell lines, which supports the view that the stem cell
properties of thyrospheres are closely related to the EMT.
One of the cardinal features of the EMT is the loss of
expression of adhesion molecules, which allows tumor
cells to detach from and migrate away from the primary
tumor site [8]. In two of the four thyrosphere lines we
tested (lines 2 and 3), however, expression of the adhesion
molecule E-cadherin was significantly upregulated rather
than downregulated relative to the corresponding primary
tumor cell lines. Chao et al. have noted that E-cadherin
expression is largely restored in cells that have already
metastasized. In this context, it is thus interesting to note
that lines 2 and 3 were both derived from secondary lesions
(see Supplementary Table 1) [44, 45].
CSC lines 1, 2, and 4 were characterized by the activation
of several EMT-related RTKs that are known to be direct
targets of crizotinib.AlthoughourCSC line cell viabilitywas
not significantly inhibited after exposure to the drug, pro-
liferation of all the primary cell cultures was reduced by
nanomolar to micromolar concentrations of crizotinib. The
discrepancy between crizotinib’s effects in our primary
thyroid cancer cell lines and the CSC sub-populations of
these lines is suggestive of a phenomenon of resistance to the
drug in a subpopulation of each tumor.Although themajority
of the cells in the tumor mass are inhibited by the drug, the
thyrospheres remain unresponsive likely thanks to their
distinctive RTK activation profiles. Subsequent selection of
these cells may lead to disease recurrence and/or progres-
sion. ‘‘Switching off’’ a few of the kinases activated in these
cells (possibly even one) may be sufficient to counteract this
resistance, as previously demonstrated in other cancers [46–
48]. Accordingly, the concept of ‘‘combination therapy’’ is
increasingly relevant in treatment of aggressive thyroid
carcinoma [49].
In conclusion, our findings highlight the variability of
CSC populations from different tumors. They also support
the role played by the EMT process in thyrospheres and the
hypothesis that thyrospheres are involved in thyroid cancer
progression and their resistance to treatment. In our study,
the lack of other experimental models as well as the
reduced number of samples analyzed constituted a limita-
tion in identifying some more complicated molecular
mechanisms of drug resistance.
Tailored approaches are needed for the management of
poorly differentiated/metastatic thyroid cancers that are
refractory to conventional therapies. Ongoing attempts to
characterize the molecular profiles of CSCs from individual
thyroid cancers will provide insight into the process of thyroid
carcinogenesis and potentially useful information for devel-
oping individualized targeted therapies for these tumors.
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